Compare PROP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | GANX |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 52.2M |
| IPO Year | 2008 | 2021 |
| Metric | PROP | GANX |
|---|---|---|
| Price | $0.31 | $1.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.50 | ★ $6.60 |
| AVG Volume (30 Days) | ★ 1.2M | 694.5K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | $55,180.00 |
| Revenue This Year | $85.81 | N/A |
| Revenue Next Year | $11.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.30 | $0.94 |
| 52 Week High | $2.55 | $4.34 |
| Indicator | PROP | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 48.29 |
| Support Level | N/A | $0.94 |
| Resistance Level | $0.44 | $1.91 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 2.94 | 66.66 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.